BYAH — Stock Film
STOCK FILMSCENE 1/11BYAH · $2.38
Stock Expert AI presents
BYAH
Park Ha Biological Technology Co., Ltd. Ordinary Shares
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Park Ha Biological Technology Co., Ltd. Ordinary Shares. What it actually does.

Develops skincare products under the “Park Ha” brand. Operates as an investment holding company. Now — the numbers.

on the stock market since 2024
41 employees
$1.8M market value
Revenue last year:
$2.5M
The loss that same year:
$24.4M
For every $1 it earns, the company spends $11.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.

$931K
2021
2022
2023
2024
$2.5M
2025
In the vault right now:
$3.8M
DEBT: $180K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
0.7×

This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 45% of them.

No analyst target is on record for this company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
7
very weak

Clearly below the class average.

FINANCIAL STRENGTH
31
very weak

Clearly below the class average.

VALUATION
45
weak

Clearly below the class average.

GROWTH
12
very weak

Clearly below the class average.

PRICE MOMENTUM
2
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $2.5M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $24.4M against $2.5M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
17 / 100 · MoonshotScore

On our five-subject report card, BYAH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: BYAH is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 12, 2026 · stockexpertai.com · Stock Film